Compare Aurobindo Pharma with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs SHASUN PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA SHASUN PHARMA AUROBINDO PHARMA/
SHASUN PHARMA
 
P/E (TTM) x 18.7 123.9 15.1% View Chart
P/BV x 3.8 8.5 44.8% View Chart
Dividend Yield % 0.3 0.2 118.3%  

Financials

 AUROBINDO PHARMA   SHASUN PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
SHASUN PHARMA
Mar-14
AUROBINDO PHARMA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs83094 881.1%   
Low Rs52746 1,155.9%   
Sales per share (Unadj.) Rs333.9214.2 155.9%  
Earnings per share (Unadj.) Rs40.45.3 756.3%  
Cash flow per share (Unadj.) Rs51.815.8 327.2%  
Dividends per share (Unadj.) Rs2.501.00 250.0%  
Dividend yield (eoy) %0.41.4 25.8%  
Book value per share (Unadj.) Rs237.153.3 444.5%  
Shares outstanding (eoy) m585.9156.62 1,034.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.00.3 622.7%   
Avg P/E ratio x16.813.1 128.4%  
P/CF ratio (eoy) x13.14.4 296.7%  
Price / Book Value ratio x2.91.3 218.4%  
Dividend payout %6.218.7 33.1%   
Avg Mkt Cap Rs m397,5693,958 10,045.4%   
No. of employees `00017.9NA-   
Total wages/salary Rs m25,8492,164 1,194.8%   
Avg. sales/employee Rs Th10,956.9NM-  
Avg. wages/employee Rs Th1,447.7NM-  
Avg. net profit/employee Rs Th1,324.3NM-  
INCOME DATA
Net Sales Rs m195,63612,127 1,613.2%  
Other income Rs m1,553229 677.2%   
Total revenues Rs m197,18912,356 1,595.9%   
Gross profit Rs m39,5191,009 3,916.5%  
Depreciation Rs m6,680594 1,125.3%   
Interest Rs m2,626415 632.6%   
Profit before tax Rs m31,767230 13,829.8%   
Minority Interest Rs m270-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,269-73 -9,995.2%   
Profit after tax Rs m23,645302 7,826.4%  
Gross profit margin %20.28.3 242.8%  
Effective tax rate %22.9-31.7 -72.3%   
Net profit margin %12.12.5 485.1%  
BALANCE SHEET DATA
Current assets Rs m153,6456,884 2,231.8%   
Current liabilities Rs m120,4298,456 1,424.2%   
Net working cap to sales %17.0-13.0 -131.0%  
Current ratio x1.30.8 156.7%  
Inventory Days Days13562 219.4%  
Debtors Days Days64108 59.2%  
Net fixed assets Rs m103,9094,970 2,090.6%   
Share capital Rs m586113 517.1%   
"Free" reserves Rs m138,3222,875 4,811.4%   
Net worth Rs m138,9083,020 4,599.3%   
Long term debt Rs m1,8001,817 99.0%   
Total assets Rs m264,54413,347 1,982.0%  
Interest coverage x13.11.6 843.1%   
Debt to equity ratio x00.6 2.2%  
Sales to assets ratio x0.70.9 81.4%   
Return on assets %9.95.4 184.8%  
Return on equity %17.010.0 170.2%  
Return on capital %23.813.3 178.9%  
Exports to sales %49.646.4 107.1%   
Imports to sales %18.814.2 131.8%   
Exports (fob) Rs m97,0915,622 1,727.1%   
Imports (cif) Rs m36,7411,728 2,126.6%   
Fx inflow Rs m97,3165,843 1,665.6%   
Fx outflow Rs m40,5892,173 1,867.8%   
Net fx Rs m56,7273,669 1,545.9%   
CASH FLOW
From Operations Rs m16,220398 4,079.6%  
From Investments Rs m-28,768-1,635 1,759.5%  
From Financial Activity Rs m19,1911,309 1,466.5%  
Net Cashflow Rs m6,65671 9,348.9%  

Share Holding

Indian Promoters % 54.1 39.2 138.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 3.6 220.8%  
FIIs % 27.7 17.6 157.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 39.6 25.8%  
Shareholders   69,601 20,750 335.4%  
Pledged promoter(s) holding % 8.6 12.3 69.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  DIVIS LABORATORIES  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 7, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS